Re: SSRI-induced sexual dysfunction : clinical study of 344 patients

[Guest guest]

" In only 5.8% of patients, the dysfunction disappeared completely

within 6 months "

Are you kidding me? This is one of the most striking PSSD papers i

have seen. I think this shows that PSSD is pretty common and should

be investigated more. This pretty much shows that 94% of patients get

PSSD for at least 6 months.

[Guest guest]

It's 58%, not 5.8%...but t's still a good, albeit inadvertant,

demonstration of the existence of PSSD. contacted Dr. Montejo, the

senor author of this study, and he refuses to beleve how own data.

Complete denial.

Anyway, The paper has been lsted in the Wikipedia article for quite

some time now. It has also been cited in my two case report papers

(P & P and JSM).

Vornan

>

> " In only 5.8% of patients, the dysfunction disappeared completely

> within 6 months "

>

> Are you kidding me? This is one of the most striking PSSD papers i

> have seen. I think this shows that PSSD is pretty common and should

> be investigated more. This pretty much shows that 94% of patients get

> PSSD for at least 6 months.

>

[Guest guest]

Whoops, got a little carried away there.It's still a high incidence of

sexual dysfunction though.

[Guest guest]

I still wonder why it says so in the abstract? Is it a typo or

something like that. Here is the exact quote, copy paste.

" In only 5.8% of patients, the dysfunction disappeared completely

within 6 months, but 81.4% showed no improvement at all by the end of

this period. Twelve of 15 patients experienced total improvement when

the treatment was changed to moclobemide (450-600 mg/day), and 3 of 5

patients improved when treatment was changed to amineptine (200 mg/day) "

It says that 81,4% showed no improvement at all. That is a very high

percentage of sexual dysfunction.

[Guest guest]

Well, the 5.8% refers to patients who saw improvement while still on

SSRIs; it's not about people who have stopped taking them. So it

doesn't prove the existence of PSSD. In another paper by the same

authors they do accidentally prove the existence of PSSD - while

swictching them to amineptine, only 55% had improvement in sexual

function, compared to 4% in the control group.

Vornan

>

> " In only 5.8% of patients, the dysfunction disappeared completely

> within 6 months "

>

>

> http://cat.inist.fr/?aModele=afficheN & cpsidt=2799162

>

>

> Titre du document / Document title

> SSRI-induced sexual dysfunction : Fluoxetine, paroxetine,

sertraline,

> and fluvoxamine in a prospective, multicenter, and descriptive

> clinical study of 344 patients

> Auteur(s) / Author(s)

> MONTEJO-GONZALEZ A. L. (1) ; LLORCA G. ; IZQUIERDO J. A. ; LEDESMA

A.

> ; BOUSONO M. ; CALCEDO A. ; CARRASCO J. L. ; CIUDAD J. ; DANIEL E. ;

> DE LA GANDARA J. ; DERECHO J. ; FRANCO M. ; GOMEZ M. J. ; MACIAS J.

A.

> ; MARTIN T. ; PEREZ V. ; SANCHEZ J. M. ; SANCHEZ S. ; VICENS E. ;

> Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

> (1) Servicio de Psiquiatria, Hospital Universitario de Salamanca,

> Paseo de S. Vicente 58, 37007 Salamanca, ESPAGNE

> Résumé / Abstract

> The authors analyzed the incidence of sexual dysfunction (SD) with

> different selective serotonin reuptake inhibitors (SSRIs;

fluoxetine,

> fluvoxamine, paroxetine, and sertraline) and hence the qualitative

and

> quantitative changes in SD throughout time in a prospective and

> multicenter study. Outpatients (192 women and 152 men; age =

39.6±11.4

> years) under treatment with SSRIs were interviewed with an SD

> questionnaire designed for this purpose by the authors and that

> included questions about the following: decreased libido, delayed

> orgasm or anorgasmia, delayed ejaculation, inability to ejaculate,

> impotence, and general sexual satisfaction. Patients with the

> following criteria were included: normal sexual function before SSRI

> intake, exclusive treatment with SSRIs or treatment associated with

> benzodiazepines, previous heterosexual or self-erotic current sexual

> practices. Excluded were patients with previous sexual dysfunction,

> association of SSRIs with neuroleptics, recent hormone intake, and

> significant medical illnesses. There was a significant increase in

the

> incidence of SD when physicians asked the patients direct questions

> (58%) versus when SD was spontaneously reported (14%). There were

some

> significant differences among different SSRIs: paroxetine provoked

> more delay of orgasm or ejaculation and more impotence than

> fluvoxamine, fluoxetine and sertraline (X[2], p <.05). Only 24.5% of

> the patients had a good tolerance of their sexual dysfunction.

Twelve

> male patients who suffered from premature ejaculation before the

> treatment preferred to maintain delayed ejaculation, and their

sexual

> satisfaction, and that of their partners, clearly improved. Sexual

> dysfunction was positively correlated with dose. Patients

experienced

> substantial improvement in sexual function when the dose was

> diminished or the drug was withdrawn. Men showed more incidence

> ofsexual dysfunction than women, but women's sexual dysfunction was

> more intense than men's. In only 5.8% of patients, the dysfunction

> disappeared completely within 6 months, but 81.4% showed no

> improvement at all by the end of this period. Twelve of 15 patients

> experienced total improvement when the treatment was changed to

> moclobemide (450-600 mg/day), and 3 of 5 patients improved when

> treatment was changed to amineptine (200 mg/day).

> Revue / Journal Title

> Journal of sex and marital therapy (J. sex marital ther.) ISSN

> 0092-623X CODEN JSMTB5

> Source / Source

> 1997, vol. 23, no3, pp. 176-194 (130 ref.)

> Langue / Language

> Anglais

> Editeur / Publisher

> Human Sciences Press, New York, NY, ETATS-UNIS (1974) (Revue)

> Mots-clés anglais / English Keywords

> Fluoxetine ; Paroxetine ; Sertraline ; Fluvoxamine ; Incidence ;

> Epidemiology ; Public health ; Toxicity ; Chemotherapy ; Treatment ;

> Sexual behavior disorder ; Multicenter study ; Sex ; Human ;

> Antidepressant agent ; Psychotropic ; Reuptake inhibitor ;

Serotonin ;

> Mots-clés français / French Keywords

> Fluoxétine ; Paroxétine ; Sertraline ; Fluvoxamine ; Incidence ;

> Epidémiologie ; Santé publique ; Toxicité ; Chimiothérapie ;

> Traitement ; Trouble comportement sexuel ; Etude multicentrique ;

Sexe

> ; Homme ; Antidépresseur ; Psychotrope ; Inhibiteur recapture ;

> Sérotonine ;

> Mots-clés espagnols / Spanish Keywords

> Fluoxetina ; Paroxetina ; Sertralina ; Fluvoxamina ; Incidencia ;

> Epidemiología ; Salud pública ; Toxicidad ; Quimioterapia ;

> Tratamiento ; Trastorno conducta sexual ; Estudio multicéntrico ;

Sexo

> ; Hombre ; Antidepresor ; Psicotropo ; Inhibidor recaptura ;

Serotonina ;

> Localisation / Location

> INIST-CNRS, Cote INIST : 15755, 35400006921556.0020

>

> Copyright 2007 INIST-CNRS. All rights reserved

> Toute reproduction ou diffusion même partielle, par quelque procédé

ou

> sur tout support que ce soit, ne pourra être faite sans l'accord

> préalable écrit de l'INIST-CNRS.

> No part of these records may be reproduced of distributed, in any

form

> or by any means, without the prior written permission of INIST-CNRS.

> Nº notice refdoc (ud4) : 2799162

>

[Guest guest]

Anymonus777 wrote:

Here is the exact quote, copy paste."In only 5.8% of patients, the dysfunction disappeared completelywithin 6 months, but 81.4% showed no improvement at all by the end ofthis period. Twelve of 15 patients experienced total improvement whenthe treatment was changed to moclobemide (450-600 mg/day), and 3 of 5patients improved when treatment was changed to amineptine (200 mg/day)"

Can it be found out how they got hold of amineptine? Touted for its alleged prosexual effects, it's supposedly only possible to get hold of on the gray market from China at a very high price. // Ulf

[Guest guest]

if i understand that rite the guy that performed the test does not

believe his own data?

and only in 58% of patents the dysfunction disappeared completely

after 6 months?

if that is true those figures tie in to my genetic theory, as about

50% of the population have at least one of the two genes that cause

gilberts syndrome.

this compounds my beliefs further towards the fact that people with

at least one of those genes are more susceptible to adverse effects

of ssris! (i think there's definitely some thing behind what im

saying here guys!)

i think the drug company's know this! and its being suppressed as 50%

of the population are unsuitable to consume many of today's

pharmaceuticals!

this is why they are currently researching and trying to develop

specifically created drugs to an individuals genetic make up!

> >

> > " In only 5.8% of patients, the dysfunction disappeared completely

> > within 6 months "

> >

> > Are you kidding me? This is one of the most striking PSSD papers i

> > have seen. I think this shows that PSSD is pretty common and

should

> > be investigated more. This pretty much shows that 94% of patients

get

> > PSSD for at least 6 months.

> >

>